2015
RIG-I-Induced Type I IFNs Promote Regeneration of the Intestinal Stem Cell Compartment during Acute Tissue Damage
Fischer J, Bscheider M, Eisenkolb G, Wintges A, Lindemans C, Heidegger S, Monette S, Calafiore M, Rodriguez K, Lieberman S, Liu C, Peschel C, Docampo M, Velardi E, Jenq R, Hanash A, Dudakov J, Haas T, van den Brink M, Poeck H. RIG-I-Induced Type I IFNs Promote Regeneration of the Intestinal Stem Cell Compartment during Acute Tissue Damage. Blood 2015, 126: 3072. DOI: 10.1182/blood.v126.23.3072.3072.Peer-Reviewed Original ResearchTotal body irradiationEpithelial regenerationAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationAcute intestinal injuryEpithelial cellsIntestinal barrier damageStem cell transplantationAcute tissue damageType I IFNsType I IFNActivation of RIGInnovative therapeutic strategiesIntestinal epithelial cellsRegenerative functionMechanism of actionHost diseaseIntestinal injuryBody irradiationBarrier damageCell transplantationDeficient miceViral challengePreclinical modelsWorse graft
2005
Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication
Zhu H, Butera M, Nelson D, Liu C. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virology Journal 2005, 2: 80. PMID: 16146571, PMCID: PMC1232870, DOI: 10.1186/1743-422x-2-80.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntiviral AgentsBase SequenceCell LineGenes, MHC Class IHepacivirusHepatitis CHumansInterferon Regulatory Factor-1Interferon Type IInterferon-alphaInterferon-Stimulated Gene Factor 3Interleukin-10InterleukinsJanus KinasesMolecular Sequence DataRNA, ViralSignal TransductionSTAT Transcription FactorsVirus ReplicationConceptsInterferon-stimulated genesIL-28AAntiviral activityAntiviral efficacyHuman hepatoma cellsSide effectsChronic hepatitis C viral infectionHepatitis C viral infectionViral RNA replicationAntiviral response ratesHCV subgenomic RNA replicationIFNα-based therapyGenotype 1 infectionHCV chronic infectionC viral infectionIL-10 receptorIL-10 treatmentHLA class IType I IFNJAK-STATRNA replicationDose-dependent mannerHepatoma cellsExpression of ISGsUndesirable side effects